A 2018 study observed that an Adenovirus-vectored vaccine containing the ZIKV prM-E elicited robust humoral and cellular immune responses (but lower than those elicited with our DNA-ZIKV/MVA-ZIKV) in immunocompetent BALB/c mice and provided sterilizing protection against ZIKV infection in Interferon receptor-deficient (A129) mice [55]. Here, IFNAR2 is linked to Zika virus infectious disease.